Literature DB >> 22718218

Long-term mortality after pneumonia.

Eric M Mortensen1, Mark L Metersky.   

Abstract

Although pneumonia is currently considered the eighth leading cause of death in the United States this estimate includes only short-term mortality. Evidence suggests that pneumonia may have significant longer-term effects and that hospitalization for pneumonia is associated with higher long-term mortality than for many other major medical conditions. Reasons for this increased mortality appear to be due to several factors, including cardiovascular disease, neoplasms, and alterations in immune function. Clinicians need to be aware that even for those patients who survive the initial episode of pneumonia there will still be an impact upon their potential survival for the coming years. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2012        PMID: 22718218     DOI: 10.1055/s-0032-1315644

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  11 in total

1.  Is Pneumonia a Risk Factor or a Risk Marker for Long-Term Mortality?

Authors:  Carlos G Grijalva
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

2.  Hyperlipidaemia and mortality among patients hospitalised with pneumonia: retrospective cohort and propensity score matched study.

Authors:  Mohammed Yousufuddin; Umesh M Sharma; Sumit Bhagra; Mohammad Hassan Murad
Journal:  BMJ Open Respir Res       Date:  2021-03

Review 3.  Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease.

Authors:  Helen C Steel; Riana Cockeran; Ronald Anderson; Charles Feldman
Journal:  Mediators Inflamm       Date:  2013-12-25       Impact factor: 4.711

4.  Impact of an Educational Program to Reduce Healthcare Resources in Community-Acquired Pneumonia: The EDUCAP Randomized Controlled Trial.

Authors:  Jordi Adamuz; Diego Viasus; Antonella Simonetti; Emilio Jiménez-Martínez; Lorena Molero; Maribel González-Samartino; Elena Castillo; María-Eulalia Juvé-Udina; María-Jesús Alcocer; Carme Hernández; María-Pilar Buera; Asunción Roel; Emilia Abad; Adelaida Zabalegui; Pilar Ricart; Anna Gonzalez; Pilar Isla; Jordi Dorca; Carolina Garcia-Vidal; Jordi Carratalà
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

5.  Predicting 1-year mortality after hospitalization for community-acquired pneumonia.

Authors:  Ane Uranga; Jose M Quintana; Urko Aguirre; Amaia Artaraz; Rosa Diez; Silvia Pascual; Aitor Ballaz; Pedro P España
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

6.  Research in community-acquired pneumonia: the next steps.

Authors:  Antoni Torres; Igancio Martín-Loeches; Rosario Menéndez
Journal:  Intensive Care Med       Date:  2017-04-18       Impact factor: 17.440

7.  Vitamin D Status and Long-Term Mortality in Community-Acquired Pneumonia: Secondary Data Analysis from a Prospective Cohort.

Authors:  Jan C Holter; Thor Ueland; Jon Norseth; Cathrine Brunborg; Stig S Frøland; Einar Husebye; Pål Aukrust; Lars Heggelund
Journal:  PLoS One       Date:  2016-07-01       Impact factor: 3.240

Review 8.  Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.

Authors:  Antoni Torres; Francesco Blasi; Nathalie Dartois; Murat Akova
Journal:  Thorax       Date:  2015-07-28       Impact factor: 9.139

9.  Risk Factors for Long-Term Mortality after Hospitalization for Community-Acquired Pneumonia: A 5-Year Prospective Follow-Up Study.

Authors:  Jan C Holter; Thor Ueland; Pål A Jenum; Fredrik Müller; Cathrine Brunborg; Stig S Frøland; Pål Aukrust; Einar Husebye; Lars Heggelund
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

Review 10.  Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly.

Authors:  Ger T Rijkers; Laura Ie Yousif; Simone Mc Spoorenberg; Frans J van Overveld
Journal:  Risk Manag Healthc Policy       Date:  2018-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.